Volume : 7, Issue : 5, May - 2018

Cardiovascular Outcomes of Teneligliptin in patients of Type 2 Diabetes Mellitus in Rural population

Narayana Behera, Sunita Sethy, Purna Chandra Dash

Abstract :

<p>&nbsp;Aim: To evaluate the cardiovascular outcomes of teneligliptin treatment in case of Type-2 Diabetes Mellitus</p> <div>patients</div> <div>Methods: A total number of 85 patients of type 2 diabetic mellitus were selected on the basis of ADA criteria . After exercising exclusion</div> <div>criteria the selected patients were subjected to thorough clinical examination and routine investigation like complete blood count, FBS,</div> <div>2hr PPBS, HbA1c, lipid pro􀃶le, renal function tests, liver function tests, urine routine/ microscopsy , urine microalbumin, ECG,</div> <div>Echocardiography (2D and Color Doppler),CIMT (Carotid intima media thickness) in all cases.Specialised investigation like X-ray chest, USG</div> <div>of abdomen and pelvis, CT/MRI of Brain etc. were done in selective cases as per requirement.</div> <div>Patients with other oral antidiabetic agents were investigated with above tests on 􀃶rst visit and they were given teneligliptin 20mg OD</div> <div>along with the previous antidiabetic drugs. The tests were repeated after 3 months on next visit and the value were noted. Data collected</div> <div>from both the settings of the test were compared, analysed .</div> <div>Results: Clinical parameters, including body mass index and blood pressure, did not show any difference before and after treatment.</div> <div>Biochemical parameters like FBS and 2hrPPBS, HbA1c were signifacantly reduced after treatment.(FBS 136&plusmn;40.7 to 124&plusmn;8.44 in males,and</div> <div>in females 127&plusmn;35.9 to 111&plusmn;7.9,2hrPPBS 302&plusmn;73.5 mg/dl to 284&plusmn;66.6 in males and 196&plusmn;21.7 to 187&plusmn;17.3 in females). Average HbA1c at</div> <div>onset in males was 8.4&plusmn;1.5% and in females was 8.0&plusmn;0.7%. After 3 months average HbA1c in males was 7.4&plusmn;0.7% and in females was</div> <div>7.3&plusmn;0.5. The total cholesterol, LDL, TG has decreased signi􀃶cantly from baseline data in comparison to the results after 3 month.HDL also</div> <div>showed rise after treatment.Three months after treatment, there were improvements in LV systolic and diastolic function [LV ejection</div> <div>fraction, 66 &plusmn; 4.4 % to 67.5 &plusmn; 4.1 in males, 64.3 &plusmn; 4.2 % to 65.8 &plusmn; 4.1 in females, , p &lt; 0.01; E-wave velocity/A-wave velocity (E/A􀀀) ratio, 0.86&plusmn;</div> <div>0.08 to o.85&plusmn;0.05in males, 0.85 &plusmn; 0.08to 0.81&plusmn;0.06, p &lt; 0.01]. Moreover,CIMT also diminished after treatment(0.77&plusmn;0.07 to 0.73&plusmn;0.07 in</div> <div>males,0.75&plusmn;0.07 to 0.72&plusmn;0.06 in females p &lt; 0.01).</div> <div>Conclusion. DPP-4 inhibitors like teneligliptin has signi􀃶cant improvement of cardiovascular functions however more number of patients</div> <div>with longer duration of treatment require to conclude the above result .</div>